Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4052 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Schering-Plough and PTC ink hepatitis C deal

PTC’s small molecules are designed to inhibit the hepatitis C virus (HCV) internal ribosome entry site (IRES) mediated production of viral proteins. The IRES is highly conserved among

Spectrum to acquire Targent’s cancer assets

The key product to be acquired is levofolinic acid (LFA), the pure active isomer of calcium leucovorin, a component of cancer standard of care treatment 5-fluorouracil (5-FU) containing